Trader consensus on Polymarket reflects a near-even split between 75–80 (47%) and 90–95 (48.5%) flu hospitalization rates per 100,000 population for Week 12 (late March) 2026, underscoring epidemiological uncertainty in late-season peaks. CDC historical data shows week 12 rates typically range 50–100 amid waning circulation, but severity hinges on dominant strains' vaccine match—H3N2 often drives higher burdens if mismatched—and population immunity from prior exposure or vaccination. Current 2024–25 season's mild trends, with cumulative hospitalizations below recent averages per CDC surveillance, temper expectations, yet variables like emerging variants or reduced uptake could elevate rates. Key differentiator: forecasted vaccine composition for 2025–26, due from FDA in early 2025, plus winter ILI monitoring. New CDC weekly reports will refine trader positioning.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten · AktualisiertFlu Hospitalization Rate Week 12, 2026?
Flu Hospitalization Rate Week 12, 2026?
85–90 46%
90–95 46%
<75 0
75–80 0
NEW
NEW
Apr 3, 2026
<75
36%
75–80
45%
80–85
45%
85–90
46%
90–95
34%
95+
36%
85–90 46%
90–95 46%
<75 0
75–80 0
NEW
NEW
Apr 3, 2026
<75
$0 Vol.
36%
75–80
$0 Vol.
45%
80–85
$0 Vol.
45%
85–90
$0 Vol.
46%
90–95
$0 Vol.
34%
95+
$0 Vol.
36%
This market will resolve according to the cumulative influenza-associated hospitalization rate per 100,000 population for the United States, as reported for the specified week.
If the recorded data falls exactly between two brackets, this market will resolve to the higher bracket.
The resolution source for this market will be CDC FluView / FluSurv-NET (see: https://www.cdc.gov/fluview/index.html). If the FluSurv-NET hospitalization rate for the specified week is not released by 11:59 PM ET on the tenth calendar day following the date of the prior FluView weekly report release, this market will resolve to the lowest bracket.
Note: Only the CDC FluSurv-NET cumulative hospitalization rate per 100,000 population for the specified week will qualify, regardless of estimates, projections, state-level reports, or other influenza surveillance metrics published by the CDC or other sources.Trader consensus on Polymarket reflects a near-even split between 75–80 (47%) and 90–95 (48.5%) flu hospitalization rates per 100,000 population for Week 12 (late March) 2026, underscoring epidemiological uncertainty in late-season peaks. CDC historical data shows week 12 rates typically range 50–100 amid waning circulation, but severity hinges on dominant strains' vaccine match—H3N2 often drives higher burdens if mismatched—and population immunity from prior exposure or vaccination. Current 2024–25 season's mild trends, with cumulative hospitalizations below recent averages per CDC surveillance, temper expectations, yet variables like emerging variants or reduced uptake could elevate rates. Key differentiator: forecasted vaccine composition for 2025–26, due from FDA in early 2025, plus winter ILI monitoring. New CDC weekly reports will refine trader positioning.
This market will resolve according to the cumulative influenza-associated hospitalization rate per 100,000 population for the United States, as reported for the specified week.
If the recorded data falls exactly between two brackets, this market will resolve to the higher bracket.
The resolution source for this market will be CDC FluView / FluSurv-NET (see: https://www.cdc.gov/fluview/index.html). If the FluSurv-NET hospitalization rate for the specified week is not released by 11:59 PM ET on the tenth calendar day following the date of the prior FluView weekly report release, this market will resolve to the lowest bracket.
Note: Only the CDC FluSurv-NET cumulative hospitalization rate per 100,000 population for the specified week will qualify, regardless of estimates, projections, state-level reports, or other influenza surveillance metrics published by the CDC or other sources.
If the recorded data falls exactly between two brackets, this market will resolve to the higher bracket.
The resolution source for this market will be CDC FluView / FluSurv-NET (see: https://www.cdc.gov/fluview/index.html). If the FluSurv-NET hospitalization rate for the specified week is not released by 11:59 PM ET on the tenth calendar day following the date of the prior FluView weekly report release, this market will resolve to the lowest bracket.
Note: Only the CDC FluSurv-NET cumulative hospitalization rate per 100,000 population for the specified week will qualify, regardless of estimates, projections, state-level reports, or other influenza surveillance metrics published by the CDC or other sources.
Markt eröffnet: Mar 27, 2026, 11:13 AM ET
Volumen
$0Enddatum
Apr 3, 2026Markt eröffnet
Mar 27, 2026, 11:13 AM ETResolver
0x69c47De9D...This market will resolve according to the cumulative influenza-associated hospitalization rate per 100,000 population for the United States, as reported for the specified week.
If the recorded data falls exactly between two brackets, this market will resolve to the higher bracket.
The resolution source for this market will be CDC FluView / FluSurv-NET (see: https://www.cdc.gov/fluview/index.html). If the FluSurv-NET hospitalization rate for the specified week is not released by 11:59 PM ET on the tenth calendar day following the date of the prior FluView weekly report release, this market will resolve to the lowest bracket.
Note: Only the CDC FluSurv-NET cumulative hospitalization rate per 100,000 population for the specified week will qualify, regardless of estimates, projections, state-level reports, or other influenza surveillance metrics published by the CDC or other sources.Trader consensus on Polymarket reflects a near-even split between 75–80 (47%) and 90–95 (48.5%) flu hospitalization rates per 100,000 population for Week 12 (late March) 2026, underscoring epidemiological uncertainty in late-season peaks. CDC historical data shows week 12 rates typically range 50–100 amid waning circulation, but severity hinges on dominant strains' vaccine match—H3N2 often drives higher burdens if mismatched—and population immunity from prior exposure or vaccination. Current 2024–25 season's mild trends, with cumulative hospitalizations below recent averages per CDC surveillance, temper expectations, yet variables like emerging variants or reduced uptake could elevate rates. Key differentiator: forecasted vaccine composition for 2025–26, due from FDA in early 2025, plus winter ILI monitoring. New CDC weekly reports will refine trader positioning.
This market will resolve according to the cumulative influenza-associated hospitalization rate per 100,000 population for the United States, as reported for the specified week.
If the recorded data falls exactly between two brackets, this market will resolve to the higher bracket.
The resolution source for this market will be CDC FluView / FluSurv-NET (see: https://www.cdc.gov/fluview/index.html). If the FluSurv-NET hospitalization rate for the specified week is not released by 11:59 PM ET on the tenth calendar day following the date of the prior FluView weekly report release, this market will resolve to the lowest bracket.
Note: Only the CDC FluSurv-NET cumulative hospitalization rate per 100,000 population for the specified week will qualify, regardless of estimates, projections, state-level reports, or other influenza surveillance metrics published by the CDC or other sources.
If the recorded data falls exactly between two brackets, this market will resolve to the higher bracket.
The resolution source for this market will be CDC FluView / FluSurv-NET (see: https://www.cdc.gov/fluview/index.html). If the FluSurv-NET hospitalization rate for the specified week is not released by 11:59 PM ET on the tenth calendar day following the date of the prior FluView weekly report release, this market will resolve to the lowest bracket.
Note: Only the CDC FluSurv-NET cumulative hospitalization rate per 100,000 population for the specified week will qualify, regardless of estimates, projections, state-level reports, or other influenza surveillance metrics published by the CDC or other sources.
Volumen
$0Enddatum
Apr 3, 2026Markt eröffnet
Mar 27, 2026, 11:13 AM ETResolver
0x69c47De9D...Trader consensus on Polymarket reflects a near-even split between 75–80 (47%) and 90–95 (48.5%) flu hospitalization rates per 100,000 population for Week 12 (late March) 2026, underscoring epidemiological uncertainty in late-season peaks. CDC historical data shows week 12 rates typically range 50–100 amid waning circulation, but severity hinges on dominant strains' vaccine match—H3N2 often drives higher burdens if mismatched—and population immunity from prior exposure or vaccination. Current 2024–25 season's mild trends, with cumulative hospitalizations below recent averages per CDC surveillance, temper expectations, yet variables like emerging variants or reduced uptake could elevate rates. Key differentiator: forecasted vaccine composition for 2025–26, due from FDA in early 2025, plus winter ILI monitoring. New CDC weekly reports will refine trader positioning.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen